Traditionally, the number of citations that a scholarly paper receives from other papers is used as the proxy of its scientific impact. Yet citations can come from domains outside the scientific community, and one such example is through patented technologies-paper can be cited by patents, achieving technological impact. While the scientific impact of papers has been extensively studied, the technological aspect remains less known in the literature. Here we aim to fill this gap by presenting a comparative study on how 919 thousand biomedical papers are cited by U.S. patents and by other papers over time. We observe a positive correlation between citations from patents and from papers, but there is little overlap between the two domains in either the most cited papers, or papers with the most delayed recognition. We also find that the two types of citations exhibit distinct temporal variations, with patent citations lagging behind paper citations for a median of 6 years for the majority of papers. Our work contributes to the understanding of the technological impact of papers.
Introduction
Scientific research builds upon existing knowledge, and such reliance is often manifested by citing previous scientific papers. Citation flows among papers therefore have long been used to study the scientific enterprise, such as mapping knowledge domains (Rosvall & Bergstrom, 2008) , tracking the evolution of science and the emergence of new fields (Rosvall & Bergstrom, 2010; Sinatra et al., 2015) , understanding the formation of scientific consensus (Shwed & Bearman, 2010) , allocating credit in science (Shen & Barabási, 2014) , among many others. Citation-based metrics have been increasingly adopted to assess the scientific impact of various entities in the scientific community, from papers (Wang et al., 2013) and authors (Hirsch, 2005; Sinatra et al., 2016) to journals (Stigler, 1994; Varin et al., 2016) , institutions (Davis & Papanek, 1984) , and nations (King, 2004 ). Yet scholarly papers can have their impact that reaches domains beyond the scientific community. Here, we focus on one such domain-patented technologies-to study the technological impact of papers, as patents are the most widely used ones to represent technological advance (Fleming & Sorenson, 2004; Meyer, 2002) . Although such representation is limited by the possibility that not all patentable inventions have been patented, scholars have long used patent data to understand innovative activities and the development of technologies.
Papers that are cited by a patent are listed in the non-patent references (NPRs) section of a patent application and considered relevant to the application by either the applicant or the patent examiner. Apart from papers, many other types of documents may also be listed as NPRs, such as books, Web pages, etc. Patent law imposes an obligation on patent applicants to submit relevant "prior art" of which they are aware, including both patents and non-patent materials, and failure to do so may result in the application unpatentable. Patent examiner who reviews the application may find prior art themselves, generating additional citations, and then determines the patentability of the invention.
Studies about the analysis of patent-to-paper citation linkages started already in the 1980s. Narin & Olivastro (1992) reported a statistical analysis on the types of NPRs and the time and nation dimension of scientific NPRs. Scholars have proposed several interpretations about the patent-to-paper citation linkages. One of the most adopted ones is that the linkage signals direct knowledge flows (Jaffe et al., 1993; Azoulay et al., 2011) , that is, the occurrence of citations to a patent or a paper is argued to indicate that the inventors have benefited from the patent or the paper. This interpretation, although subject to debate (Meyer, 2000) and limited by the fact that patent examiners can also add citations (Alcácer & Gittelman, 2006; Alcácer et al., 2009; Lemley & Sampat, 2012) , has been the basis of many studies that attempt to demonstrate how publicly-financed research contributes to technological advances and private-sector innovations (Narin et al., 1997; McMillan et al., 2000; Ahmadpoor & Jones, 2017; Azoulay et al., 2017; Li et al., 2017) , motivating further public support for scientific research. Fleming & Sorenson (2004) argued that the mechanism through which science increases the rate of invention is that science leads inventors' search process more directly to useful combinations. Other scholars have argued that patent-to-paper citations signal relatedness between science and technology (Callaert et al., 2014) .
Our work shifts the attention from interpreting the linkage to assessing the technological impact of papers. In this regard, a related line of literature is the examination of the broader impact of research beyond the traditional scientific community. Existing work has examined how papers are covered by news media (Phillips et al., 1991) , used in the development of drug products (Williams et al., 2015) , referenced in clinical guidelines (Grant et al., 2000) , and mentioned on the social Web (e.g., Twitter and Wikipedia) (Thelwall et al., 2013) , among many other outlets. Our work extends this line of literature by focusing on the technological community, which hitherto has been less explored, and investigates how papers are cited by patents. Moreover, we emphasize citation growth over time rather than simple citation counts at a particular time point, allowing us to explore the dynamics of the utilization of scientific research for technology development. The only study that is similar to our work is the one by Ding et al. (2017) . However, we not only look at the entire citation history of papers as opposed to two five-year time windows considered by them, but also make a comparison of citations received from patents and from papers.
Based on the cohort of biomedical papers that have received citations from U.S. patents, we perform a comparative study on how they are cited by patents and by other papers over time. We report a set of stylized facts about the two types of citations. First, similar to paper citations, patent citations are also heterogeneously distributed. Yet, highly-cited papers in the two domains have small overlap. Second, there are delayed-recognition papers that achieve high popularity among patents after years of dormant. Third, patent citations generally lag behind paper citations for the majority of papers.
Data and methods
For each paper, we assembled two types of citations, namely those from other papers and from patents. We first describe the patent citation case. We focused only on U.S. patents, due to the public availability of patent bibliographic data over a long period of time. To get citation information from patents, we downloaded the front page bibliographic data of all utility patents granted by the United States Patent and Trademark Office (USPTO) between 1976 and 2013 from https://bulkdata.uspto.gov, and excluded withdrawn patents (https://www.uspto.gov/patents-application-process/patent-search/withdrawn-patent-numbers). Each patent included a list of references containing previously issued patents and optional NPRs that can refer to essentially anything, including books, papers, patent applications, online resources, etc. As we are interested in papers, we further excluded patents without any NPR, ending up with 1, 637, 072 patents.
We then matched their NPRs with papers indexed in MEDLINE, a large-scale bibliographic database for biomedical research literature maintained by the National Library of Medicine (NLM). The matching steps are as follows:
1. We submitted a search query to PubMed where the search term is the entire NPR text, with the URL following: https://www.ncbi.nlm.nih.gov/pubmed/?term= [NPR] &report=uilist&format=text, which returned the matched PMID. To validate our matching results, we manually matched 208 randomly selected NPRs, and Table 1 reports the confusion matrix. For 117 cases, hand labeling and the matching method found the same paper (true positives); for 85 cases, both agreed that there was no paper matched (true negatives); and for 6 cases, our matching method deemed that there was no paper matched but manual labeling found one (false negatives). A total of 919, 222 unique papers were matched. After this integration step, we counted, for a paper published in calendar year t p , the number of patent citations it received in the t-th (t ∈ [0, L]; L = T − t p ; T = 2013) year after its publication, denoted as c P t . Note that the citing patents in each year t (calender year t p + t) are those issued at time t rather than those whose applications were submitted at t. The total number of patent citations it received until the end of the observation period is
Here we do not distinguish between citations generated by applicants or examiners, as we do not concern about knowledge spillover and examiner-added citations may also indicate the impact of papers.
To get the number of citations from papers, we turn to the Web of Science (WoS) database, as citation data is available only for PubMed Central papers. We used a version of WoS currently housed at the Indiana University Network Science Institute to retrieve the paper citation data. To locate MEDLINE papers in WoS, we used the mapping data between PMID (PubMed ID) and UT (Accession Number), which are the two identifiers used in their respective database, and successfully found 859, 085 (93.46%) MEDLINE papers in WoS. When counting citations, we only considered the following types of documents: article, review, editorial, note, and letter. For each of the papers under consideration, we denote its yearly number of citations from other papers as c A t , and C A is the total number of paper citations it received by 2013. For analysis that involved the entire MEDLINE database, we used a snapshot in 2015 that contained 23, 343, 329 papers. To get the fields of papers, we chose to use the NLM Catalog data (https://www.ncbi. nlm.nih.gov/nlmcatalog), as it is specifically created to be used in conjunction with other databases such as MEDLINE maintained by NLM. It assigns each indexed journal to one or more categories called Broad Subject Terms (e.g., Biochemistry, Cell Biology, Nursing, Health Services Research).
Results
The overarching goal of the present study is to examine how patent citations of papers are different from paper citations. To this end, we present four sets of results. First, we report in Section 3.1 descriptive statistics on the types of papers that get cited by patents, journals where these papers were published, and fields to which they belong, given that these statistics are not well-known in the existing literature. Second, in Section 3.2, we examine how total patent and paper citations differ. Next, Section 3.3 examines how patent and paper citations change over time by focusing on the delayed recognition phenomenon. Finally, Section 3.4 performs a lead-lag analysis of citation dynamics. 
Fields and journals
The 919, 222 papers that get patent citations only account for a very small portion (4%) of all 22, 975, 980 MEDLINE papers published until 2013. Our estimation is similar to the one obtained from a recent study where papers in WoS rather than MEDLINE were considered: 1.41 out of 32 million, or 4.4% of, WoS papers were cited by USPTO-issued patents (Ahmadpoor & Jones, 2017) . Table 2 shows the distribution of document types assigned by WoS for the 859, 085 MEDLINE papers indexed there. Articles contribute to the largest portion (86.6%), followed by review, note, editorial, and letter. Table 3 displays the top 20 most cited biomedical research fields, as defined by NLM as Broad Subject Terms, which in total account for 73.1% of patent citations. For each field, we derived three statistics: (1) the total number of patent citations of all papers published in journals that belong to the field, (2) the unique number of papers that are cited by patents, and (3) the fraction of papers that are cited by patents among all papers published there. While the first two are of retrospective, the third one is of prospective, since each journal publishes different amounts of papers. Biochemistry is the most cited field, attracting 12.9% of citations from patents, followed by Science (10.6%), Molecular Biology (6.0%), Allergy and Immunology (5.2%), Cell Biology (4.2%), and Chemistry (3.7%). Here "Science" covers multi-disciplinary journals like Nature and Science, similar to the Multidisciplinary Science designated in Journal Citation Reports (JCR).
The second observation from Table 3 is that the share of citations for each field is roughly proportional to the share of the number of unique papers cited, except for the Science category. This means that multidisciplinary journals accrue patent citations disproportionately, suggesting a larger-than-average number of patent citations for papers published there.
When looking at the fraction of cited papers among all papers published ("% Published" column), we observe that the overall tendency to be cited by patents varies across fields. Among these most cited fields, Biotechnology has the largest portion (14%) of papers cited by patents. Virology, Biochemistry, Molecular Biology, Allergy and Immunology, and Cell Biology all have more than 10% of such papers. On the other hand, only 1.7% of papers belonging to Medicine get patent citations, which is similar for General Surgery. Cardiology, Neurology, Biology, and Physiology also generate a small fraction of patent-cited papers.
The last column in Table 3 indicates whether these fields belong to basic research or clinical medicine, as categorized by Narin et al. in the 1976 pioneering work on the structure of biomedical literature (Narin et al., 1976) . Although the number of basic research fields is similar to the ones belonging to clinical medicine, basic research surpass clinical medicine once we weight by total citations or unique papers. This resonates with previous results (Narin et al., 1997; McMillan et al., 2000) .
Next, we delve into journals. Table A .1 reports the top 10 field-specific journals that received the most patent citations. For each journal, we present the same set of statistics as in Table 3 . We see from Table A.1 that papers that obtained patent citations were published in leading journals. Across fields, PNAS, Journal of Biological Chemistry (JBC), a journal with a long publishing history, and Science are the top three most cited journals. They are also the three journals that published the largest number of papers that are cited by patents. Other highly-cited journals include Nature, Journal of Medicinal Chemistry, Nucleic Acids Research, and Cell.
Similar to what has been observed in Table 3 , most journals attract patent citations proportionate to their share of cited papers. But this is not the case for Cell : only 15% of Cell Biology papers were published Table A .1 also provides results from a prospective analysis. Across these fields, Annual Review of Immunology has the highest fraction (54%) of papers that are cited by patents, followed by Journal of Medicinal Chemistry (43%), Cell (38%), and EMBO Journal (30%). On the other hand, Nature and Science have a relatively low fraction, which could simply due to the fact that they are multidisciplinary journals that publish non-biomedical papers.
A final point regarding both Tables 3 and A.1 is that these results are limited by the fact that MEDLINE is a database for the biomedical research literature. As such, it may have low coverage of papers in other disciplines such as physics and engineering, especially if papers in these disciplines are not directly related to biomedicine. This may to some extent dictate our results. For example, in a seminal work by Narin et al. (1997) that studied citations from U.S. patents to papers, they found that Tetrahedron is among the top most cited Chemistry journals. However, it fails to make it top in Table A .1, because MEDLINE only has a limited coverage of papers in Tetrahedron. Future work therefore is needed to compare how our results are different from the ones based on other databases like WoS.
Total citations
How many citations does a paper receive from patents? How does it compare to citations from other papers? In this section, we investigate total citations. Tables A.2 and A.3 list the top 10 papers by total patent citations C P and paper citations C A , respectively. The paper with the highest number of paper citations in our sample happens to be the most cited one of all time (Noorden et al., 2014) .
Heterogeneity in the number of patent citations C P is present for the cohort of 919, 222 papers that got cited by patents, as evidenced from Fig. 1A where we plot the survival distribution of C P . Although 414, 981 (45.1%) papers have only one patent citation, there exists papers that are cited by thousands of patents. We fitted the distribution with the power-law function, giving us exponent α P = 2.93. For comparison, we also show in Fig. 1A the distribution of C A , the total number of paper citations, and the power-law fit yields exponent α A = 3.01. This suggests that despite paper citations are larger than patent citations-which could simply due to the fact that there is a larger pool of papers than that of patents-they exhibit similar speed of decay.
We further compare total patent and paper citations. Fig. 1B plots C P against C A in the form of heat map, where the color encodes the frequency of papers. The map features a broad band with an upward slope, indicating that papers under our consideration that have more paper citations in general tend to attract more patent citations as well. The Spearman's rank correlation coefficient between C P and C A is 0.228. Such a positive correlation persists (coefficient 0.251) if we consider all the 15, 678, 754 MEDLINE papers that can be found in WoS. We also observe that the region of the highest density is located in the lower left of the heat map, corresponding to the case where most papers have paper citations less than 100 and patent citations less than 10. The map indicates that the vast majority of papers have less patent citations than paper citations, but 22, 736 (2.65%) papers exhibit the opposite, among which 8 of the top 10 papers with most patent citations are in this case. A total of 6, 166 (0.7%) papers are cited by patents but got zero paper citation.
Are papers that are highly cited in the scientific community also highly cited in the patent sphere? We quantified the extent of overlap between the two sets of top cited papers using a similarity measure. Formally, let M P (M A ) be the set of papers with the number of patent (paper) citations no less than the threshold corresponding to a given percentile, and the similarity between M P and M A is defined as s = M P ∩ M A / M P , which measures the fraction of top cited papers by patents that are also top cited by papers. Fig. 1C shows that similarity s steadily decreases as we increase the percentile. Only 18% of the top 1% most cited papers by patents are also in the top 1% by the number of paper citations, indicating a small overlap of papers that are highly cited in both the scientific and the technology community. This 200 pattern is consistent if we consider only research articles (Fig. 1C) or papers in one filed (Fig. A.1A) .
Delayed recognition papers
The previous section has examined the total number of citations measured at the end of our observation period T = 2013, but how it reached to that number can be diverse. We now look at time-dependent citation growth. From now on, we only restrict our analysis to the cohort of 852, 919 papers that (1) were published from 1976 and onward, since patent citation data is available only starting from 1976, and (2) had at least one paper citation (C A > 0), since we are interested in the comparison between c P t and c A t . We first focus on a class of papers-the so-called "Sleeping Beauty" papers that lie dormant in a long period of time after their publication and then suddenly become highly cited. This notion has been mostly constrained within the scientific community, that is, citation curves based on which SBs are discovered are derived from how many other scientific papers have cited the focal one. Recent work has started to extend this notion to the technology domain (van Raan, 2017) , and here we investigate whether there are also SBs that are perceived as late boomer by the technology community.
To do so, we calculated the Beauty Coefficient based on the c P t and c A t curve of each paper (Ke et al., 2015) , denoted as B P and B A , respectively. Tables A.4 and A.5 report the top 10 SBs by B P and B A , respectively. Fig. 2A , which plots the distributions of B P and B A , indicates that the extent of delayed recognition of papers perceived by both the scientific and technology community spans three orders of magnitude, similar to what has been observed before (Ke et al., 2015) . Regarding individual papers, there is a negligible correlation between their B P and B A values (Spearman correlation coefficient 0.09). There is a low overlap of top SBs recognized by the two communities, as shown in Fig. 2B : only 5% of the top 1% SBs measured from patent citations also rank in the top 1% SBs measured from paper citations. This observation still holds even if we consider only articles (Fig. 2B) or papers in one field (Fig. A.1B) . These results suggest different life-cycles of patent and paper citations.
Time-dependent citation accumulation
Having looked at a particular type of papers, we now characterize the temporal variation of citations. To do so, we introduce the following parameters to describe a given citation dynamics curve c t :
It measures the number of years taken to obtain the first citation; 2. t m = arg {max t c t }. It is the number of years taken to obtain the maximum yearly citations; 3. I = 1 (∃t s.t. c t < c tm /2, t ∈ [t m + 1, L]). It indicates whether the yearly citations have decreased to half of the maximum;
The first case captures the number of years that the curve has stayed above c tm /2 after reaching its maximum, given that the curve has not fallen below half of the maximum. The second case measures the number of years taken to fall below the half of the maximum, where t h is the time when c t drops below c tm /2 for the first time.
While the first two summarize how c t reaches the maximum, the latter two characterize how c t decrease after that. As each paper is associated with two time-series, namely c (Mosmann, 1983) , published in 1983, its yearly paper citations reached the peak at the end of the observation period (t We calculated the introduced parameters for each paper in our cohort. Fig. 4 presents the distributions of these parameters across all papers, allowing us to probe overall patterns of their citation dynamics. First, Fig. 4A , which shows the cumulative distribution of t P f and t A f , indicates that almost all papers obtained their first paper citation during 5 years after publication, while only 30% of papers got cited by patents in 5 years. In general, we observe from Fig. 4B that first patent citation occurred after first paper citation was obtained (∆t f > 0) for almost all papers, and the median lag is 7 years. Focusing on t m , Fig. 4C indicates that the median number of years taken to reach maximum yearly citations is 4 and 8 years for paper and patent citations, respectively. Fig. 4D shows that the majority (78.9%) of papers obtained maximum yearly patent citations after the same event happened to paper citations (∆t m < 0), and median lag is 6 years for those papers.
Focusing on how citations decrease after the peak, for only 0.6% papers, their patent citations have not dropped below half of the maximum (I P = 0; Fig. 4E ); and 9% for the paper citation case (I A = 0; Fig. 4F ). Fig. 4H indicates that most papers belonging to this category obtain maximum citations very recently-within 3 and 7 years close to the end of the observation period for the patent and paper citation case, respectively.
For the remaining 99.4% and 91% papers whose yearly patent and paper citations have decreased below c tm /2, Fig. 4G shows that such decay is very rapid for both c 
Discussion
The increasing availability of large-scale datasets that systematically record how scholarly papers are referenced and mentioned in different channels has opened new possibilities for searching for the broader impact of research beyond the traditional scientific community. Previous studies have focused on news media, clinical guidelines, policy documents, and the social Web. In this work, we looked at another domain-patented technologies-that has received little attention so far in the literature, and studied the technological impact of papers.
Based on a newly-created dataset that links millions of non-patent references made by U.S. patents to MEDLINE papers, we compared citation statistics derived from patent references with traditional citations from papers. We found that only a small fraction-4%-of papers ever got cited by patents. These papers are mainly from Biochemistry, Molecular Biology, Allergy and Immunology, Cell Biology, and Chemistry, and are published in leading biomedical journals. For these papers, there is a positive correlation between the number of patent and paper citations, although the magnitude is low, leaving much variations to be explained by other factors. The comparison between the curves of yearly patent and paper citations reveals that the majority of papers got their first and maximum paper citation before obtaining patent citations, highlighting different life-cycles of citation dynamics. Future work is needed to uncover factors that explain the difference between patent and paper citations and examine more closely the context of patent citations. E.g., what are the technological classes of citing patents and what are the fields of cited papers? To what extent publicly-financed papers are cited by private-sector patents? Answers to these questions would contribute further to the understanding of the technological impact of scientific research. Table A .1: Field-specific rankings of top 10 journals by the total number of patent citations. We focus on the top 6 most cited fields listed in Table 3 . For each journal, we report the same set of statistics as in Table 3 . Table A .2: Top 10 papers by total number of citations from USPTO-issued patents. For brevity, the "Author" column only lists the first author. 
